US Stock MarketDetailed Quotes

SLRN Acelyrin

Watchlist
  • 4.550
  • -0.020-0.44%
Close Nov 29 13:00 ET
  • 4.770
  • +0.220+4.84%
Post 17:01 ET
456.48MMarket Cap-1719P/E (TTM)

Acelyrin Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Acelyrin Q3 2024 Earnings Date

Currency：USDNov 13, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
0
0
0
--
--
--
EPS
-0.81
-0.49
+0.32
Beat Est.
+6.90%
+43.68%
+39.50%
Analyst Rating
Buy

Nov 30, 2024

Acelyrin Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 13, 20242024/Q30.000 / 0.000--
Aug 13, 20242024/Q20.000 / 0.000--
May 13, 20242024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 13, 20242024/Q30.000 / 0.000--
Aug 13, 20242024/Q20.000 / 0.000--
May 13, 20242024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Acelyrin Earnings Reports

  • Acelyrin | 10-Q: Q3 2024 Earnings Report

    Nov 13 16:10 ET

  • Acelyrin | 8-K: ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

    Nov 13 16:09 ET

  • Acelyrin | 10-Q: Q2 2024 Earnings Report

    Aug 13 16:24 ET

  • Acelyrin | 8-K: ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

    Aug 13 16:18 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 30, 2024

    Buy

    • Buy

      60.00%

    • Hold

      40.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data